+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

The lack of fidelity of HIV reverse transcriptase as a basis for inhibitor design

The lack of fidelity of HIV reverse transcriptase as a basis for inhibitor design

FASEB Journal 7(7): A1290

(PDF emailed within 1 workday: $29.90)

Accession: 033856690

Download citation: RISBibTeXText

Related references

Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. Aids 23(12): 1605-1608, 2009

Simultaneous quantification of a non-nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry. Biomedical Chromatography 23(4): 371-381, 2008

Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Medicine 9(10): 883-896, 2008

Thermostable HIV-1 group O reverse transcriptase variants with the same fidelity as murine leukaemia virus reverse transcriptase. Biochemical Journal 436(3): 599-607, 2011

Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. Aids 13(18): 2541-2546, 2000

Enhanced fidelity of drug-selected M184V mutated reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials. INFECTIOUS DISEASES SOCIETY OF AMERICA [Author], NATIONAL INSTITUTES OF HEALTH [Author], CENTERS FOR DISEASE CONTROL AND PREVENTION [Author] 3rd Conference on retroviruses and opportunistic infections : 54, 1996

Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials. Leukemia 11 Suppl 3: 85-88, 1997

Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients. HIV Medicine 6(6): 388-395, 2005

Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. Journal of Acquired Immune Deficiency Syndromes 44(5): 506-517, 2007

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. Aids 25(18): 2269-2278, 2012

Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database of Systematic Reviews (): Cd008740-Cd008740, 2010

Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine). Current Opinion in HIV and Aids 4(6): 507-512, 2010

Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity. International Journal of Std & Aids 18(5): 343-346, 2007

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrobial Agents and ChemoTherapy 48(12): 4680-4686, 2004

Error-prone replication by HIV reverse transcriptase as a basis of drug design. Proceedings of the American Association for Cancer Research Annual Meeting 34(0): 280, 1993